Programmable DNA drug destroying all cancers, unlocking 80% of targets
FinalDose is building the first programmable drug - a single smart drug molecule that you can insert any diseased genetic code and it can search and destroy cells upon DNA recognition. Unlocking 80% of undruggable targets today. Starting with all cancers.
Founder
CEO @ FinalDose (YC P26). Oxford PhD in Oncology. Previous startup (Vivid Dx) solved a multi-decade bottleneck in sepsis diagnostics: low biomass isolation. By overcoming this hurdle, we built the world’s fastest diagnostic system - slashing wait times from 5 days to just 30 minutes. Raised $15M in venture backing.
Founder
Founder at FinalDose (YC P26). DPhil in Biochemistry from Oxford, where he spent 5 years as a postdoctoral researcher at the MRC Weatherall Institute of Molecular Medicine. Led CRISPR screening projects uncovering new druggable targets in cancer cells and built pipelines reducing hit validation time from months to 7 days. Research focuses on BRCA1-deficient cancers and PARP inhibitor resistance mechanisms.
Founder
Cofounder and CTO at FinalDose (YC P26). Oxford PhD in Computational Biology with Wellcome Trust full scholarship. Previously Data Lead at Gutsee Biotech. Developed novel machine learning method to use coevolution biology to identify genetic targets that convey drug resistance in viruses. During SARS-CoV-2 pandemic, led UK biobank analysis of human genetics susceptibility for infections
